| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
5,780,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3302 - $0.3302 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Phio Pharmaceuticals is developing therapeutics that use its INTASYL™ technology to target both tumor and immune cells by regulating genes to strengthen a patient's immune system while weakening tumor defense mechanisms. Co.'s INTASYL-based therapeutics are used to: strengthen immune cells, for example those administered as part of adoptive cell therapy (ACT), and directly modify cells in the tumor microenvironment to weaken a tumor's defense. Co.'s lead product candidate being developed by Co. in ACT is PH-762. Co.'s second product candidate in development for use in ACT is PH-894. Co.'s INTASYL compound PH-804 is also being developed for use in ACT.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
2,500 |
6,500 |
22,216 |
| Total Buy Value |
$0 |
$2,275 |
$14,195 |
$22,362 |
| Total People Bought |
0 |
1 |
2 |
2 |
| Total Buy Transactions |
0 |
1 |
4 |
12 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cauwenbergh Geert |
President & CEO |
• • – |
2013-08-28 |
4 |
B |
$3.60 |
$1,480 |
D/D |
400 |
13,800 |
2.73 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2013-08-27 |
4 |
B |
$3.70 |
$370 |
D/D |
100 |
13,400 |
2.73 |
- |
|
| Bitterman Robert J |
Director |
– • – |
2013-08-26 |
4 |
B |
$3.90 |
$1,950 |
D/D |
500 |
1,500 |
2.31 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2013-08-23 |
4 |
B |
$3.69 |
$1,113 |
D/D |
300 |
13,300 |
2.73 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2013-08-22 |
4 |
B |
$3.62 |
$1,086 |
D/D |
300 |
13,000 |
2.73 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2013-08-21 |
4 |
B |
$3.80 |
$2,584 |
D/D |
680 |
12,700 |
2.73 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2013-08-20 |
4 |
B |
$3.70 |
$2,660 |
D/D |
700 |
12,020 |
2.73 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2013-08-19 |
4 |
B |
$3.65 |
$1,191 |
D/D |
320 |
11,320 |
2.73 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2013-08-06 |
4 |
B |
$4.05 |
$1,418 |
D/D |
350 |
11,000 |
2.73 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2013-08-05 |
4 |
B |
$4.00 |
$2,605 |
D/D |
650 |
10,650 |
2.73 |
- |
|
| Bitterman Robert J |
Director |
– • – |
2013-08-05 |
4 |
B |
$4.01 |
$4,083 |
D/D |
1,000 |
1,000 |
2.31 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2013-07-31 |
4 |
B |
$4.02 |
$671 |
D/D |
167 |
10,000 |
2.73 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2013-07-31 |
4 |
B |
$4.10 |
$2,050 |
D/D |
500 |
9,833 |
2.73 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2013-07-29 |
4 |
B |
$4.54 |
$2,270 |
D/D |
500 |
9,333 |
2.73 |
- |
|
| Cauwenbergh Geert |
President & CEO |
• • – |
2013-07-26 |
4 |
B |
$4.87 |
$2,435 |
D/D |
500 |
8,833 |
2.73 |
- |
|
| Advanced Rna Technologies, Llc |
10% Owner |
– – • |
2013-07-23 |
4 |
D |
$0.16 |
$4,424 |
D/D |
(28,000) |
38,820,446 |
|
- |
|
| Advanced Rna Technologies, Llc |
10% Owner |
– – • |
2013-07-19 |
4 |
D |
$0.15 |
$16,641 |
D/D |
(111,684) |
38,918,656 |
|
- |
|
| Advanced Rna Technologies, Llc |
10% Owner |
– – • |
2013-07-18 |
4 |
D |
$0.15 |
$30,600 |
D/D |
(200,000) |
38,960,130 |
|
- |
|
| Advanced Rna Technologies, Llc |
10% Owner |
– – • |
2013-07-17 |
4 |
D |
$0.16 |
$16,000 |
D/D |
(100,000) |
39,160,130 |
|
- |
|
| Advanced Rna Technologies, Llc |
10% Owner |
– – • |
2013-07-11 |
4 |
D |
$0.20 |
$19,805 |
D/D |
(100,000) |
39,260,130 |
|
- |
|
| Advanced Rna Technologies, Llc |
10% Owner |
– – • |
2013-07-10 |
4 |
D |
$0.20 |
$44,880 |
D/D |
(230,000) |
39,360,130 |
|
- |
|
| Advanced Rna Technologies, Llc |
10% Owner |
– – • |
2013-07-05 |
4 |
D |
$0.19 |
$22,945 |
D/D |
(118,180) |
39,590,130 |
|
- |
|
| Advanced Rna Technologies, Llc |
10% Owner |
– – • |
2013-07-03 |
4 |
D |
$0.19 |
$19,375 |
D/D |
(100,000) |
39,708,310 |
|
- |
|
| Advanced Rna Technologies, Llc |
10% Owner |
– – • |
2013-07-02 |
4 |
D |
$0.19 |
$7,612 |
D/D |
(39,249) |
39,808,310 |
|
- |
|
| Advanced Rna Technologies, Llc |
10% Owner |
– – • |
2013-07-01 |
4 |
D |
$0.20 |
$19,675 |
D/D |
(100,000) |
39,847,559 |
|
- |
|
238 Records found
|
|
Page 8 of 10 |
|
|
